Evidence map›Paper›PMID 41769699›Full record

ReviewFrontiers in pharmacology2026

Polydatin in respiratory diseases: multi-target mechanisms and therapeutic potential.

Chanjun Wan, Xinyang Liu, Yueqi Xu, Li Kang, Xuelong Yu, Min Wang, Min Zhao, Xinhan Li, Zhengtao Chen, Jianguang Wu and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Chanjun Wan *Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.
Xinyang Liu *Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.
Yueqi XuAffiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.
Li KangJiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.
Xuelong YuAffiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.
Min WangJiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.
Min ZhaoJiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.
Xinhan LiJiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.
Zhengtao ChenAffiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.
Jianguang WuAffiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.
Liangji LiuJiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.
Xuemei XuJiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Respiratory diseases constitute a heterogeneous group of disorders that primarily involve the lungs. Driven by worsening air pollution, tobacco use, occupational exposures, the COVID-19 pandemic, and population aging, they show persistently high incidence with rising mortality and disability, posing a major global public-health challenge. Current pharmacotherapies-principally antibiotics, glucocorticoids, β

Indexed as

molecular targetspharmacological mechanismpolydatinrespiratory diseasessignaling pathways

Identifiers

PMID41769699
PMCPMC12946669

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.